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BACKGROUND: Endocrine therapies of breast cancer are effective but ultimately fail because of the development of treatment
resistance. We have previously revealed several genes leading to tamoxifen resistance in vitro by retroviral insertion mutagenesis. To
understand the manner in which these genes yield tamoxifen resistance, their effects on global gene expression were studied and
those genes resulting in a distinct gene expression profile were further investigated for their clinical relevance.
METHODS: Gene expression profiles of 69 human breast cancer cell lines that were made tamoxifen resistant through retroviral
insertion mutagenesis were obtained using oligonucleotide arrays and analysed with bioinformatic tools. mRNA levels of NCOR2 and
CITED2 in oestrogen receptor-positive breast tumours were determined by quantitative RT–PCR. mRNA levels were evaluated for
association with metastasis-free survival (MFS) in 620 patients with lymph node-negative primary breast cancer who did not receive
systemic adjuvant therapy, and with clinical benefit in 296 patients receiving tamoxifen therapy for recurrent breast cancer.
RESULTS: mRNA expression profiles of most tamoxifen-resistant cell lines were strikingly similar, except for the subgroups of cell lines
in which NCOR2 or CITED2 were targeted by the retrovirus. Both NCOR2 and CITED2 mRNA levels were associated with MFS, that
is, tumour aggressiveness, independently of traditional prognostic factors. In addition, high CITED2 mRNA levels were predictive for a
clinical benefit from first-line tamoxifen treatment in patients with advanced disease.
CONCLUSIONS: Most retrovirally targeted genes yielding tamoxifen resistance in our cell lines do not impose a distinctive expression
profile, suggesting that their causative role in cell growth may be accomplished by post-transcriptional processes. The associations of
NCOR2 and CITED2 with outcome in oestrogen receptor-positive breast cancer patients underscore the clinical relevance of
functional genetic screens to better understand disease progression, which may ultimately lead to the development of improved
treatment options.
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Tamoxifen is widely applied in the treatment of breast cancer. Its
efficacy has been established in both the adjuvant setting to reduce
recurrences in localised disease (Early Breast Cancer Trialists’
Collaborative Group, 2005) and in the palliative management
of patients with advanced disease (Jaiyesimi et al, 1995; Jordan,
1995; Osborne, 1998). In agreement with its biological function as
an anti-oestrogen, tamoxifen requires the presence of the
oestrogen receptor (ER) alpha. But a substantial number of ERa-
positive breast cancer patients will not benefit from tamoxifen
treatment because of intrinsic or de novo resistance. Furthermore,
nearly all responsive patients will experience disease progression
because of the development of acquired resistance. Although
other anti-oestrogens and aromatase inhibitors have been deve-
loped, resistance to these compounds will occur (Nabholtz
et al, 2000; Mouridsen et al, 2003; Paridaens et al, 2003;
Howell, 2006). Despite intense research in the last few decades
into the failure of endocrine therapies (Ali and Coombes, 2002;
Clarke et al, 2003; Jansen et al, 2005; Osborne et al, 2005; Riggins
et al, 2007; Creighton et al, 2008; Hurtado et al, 2008; Iorns et al,
2008), more insight into the underlying mechanisms is definitely
needed.
Previously, we executed a non-biased functional genetic screen
in an oestrogen-dependent human breast cancer cell model, aimed
at identifying genes causing tamoxifen resistance. Insertion of a
defective retrovirus into the genome randomly introduced
individual genetic changes in ZR-75-1 cells (Dorssers et al,
1993). Infected cells were then selected for their ability to
proliferate while being exposed to tamoxifen. From these cultures,
79 stable cell lines were established. Using various molecular
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sstrategies, common virus insertion sites (cVIS) were mapped,
enabling the identification of candidate genes that cause the
resistant phenotype. These retroviral targets were collectively
termed breast cancer anti-oestrogen-resistance (BCAR) genes.
Ultimate proof for the role of seven target genes (AKT1, AKT2,
BCAR1, BCAR3, EGFR, GRB7 and TRERF1) was obtained by cDNA
transfection into oestrogen-dependent cancer cells, transforming
them into a tamoxifen-resistant phenotype (Van Agthoven et al,
1998, 2009b; Brinkman et al, 2000).
To elucidate the manner in which these retroviral target genes
induce tamoxifen resistance in ZR-75-1 cells, we assessed whether
differences in gene expression patterns existed between the
different groups of tamoxifen-resistant cell lines. Two candidate
target genes, CITED2 and NCOR2, yielding distinct gene expression
profiles when compared with other cell lines, were analysed for
their clinical relevance in terms of tamoxifen resistance and
tumour aggressiveness.
MATERIALS AND METHODS
Cell culture
The panel of tamoxifen-resistant cell lines was previously
generated by retrovirus infection and selection for resistance
to 4-hydroxy-tamoxifen (OH-Tam, Sigma-Aldrich Chemie BV,
Zwijndrecht, The Netherlands) (Dorssers et al, 1993). Cell lines
were cultured in RPMI supplemented with 15% bovine calf serum,
10% CRIP supernatant and 1mM of OH-Tam as described before
(Dorssers et al, 1993).
Gene expression profiling
Total RNA was prepared by direct lysis with RNA-Bee (Bio-
connect, Huissen, The Netherlands) of approximately 80%
confluent cells. cDNA synthesis was performed using an T7dT-
oligo primer, 3mg of total RNA and reverse transcriptase (Super-
script II, Invitrogen, Breda, The Netherlands). Second-strand
synthesis was carried out by E.coli ligase, E.coli DNA polymerase
(Invitrogen) and RNase H (Promega Benelux b.v., Leiden, The
Netherlands). The double-stranded cDNA was purified on
Quiaquick PCR columns (Qiagen, Hilden, Germany). In vitro
transcription using the T7 Megascript Kit (Ambion, Austin, TX,
USA) was used to produce amplified RNA (aRNA). Further details
are presented in the Supplementary information.
Spotted oligo microarrays with the Operon V3.0 library (35K
Human, http://omad.operon.com/humanV3) were obtained from
the Netherlands Cancer Institute Central Microarray Facility (NKI-
CMF). Protocols for sample preparation were taken from the NKI-
CMF website (http://microarrays.nki.nl) and are detailed elsewhere
(Meester-Smoor et al, 2008). In short, 1mg of amplified RNA was
labelled using the ULS-Cy3/5 aRNA fluorescent labelling kit
(Kreatech, Amsterdam, The Netherlands), and was used for
hybridisation (Supplementary information). Two independent
samples of a cell line were hybridised against the reference and
one of them was also used in a dye-swap hybridisation. Hybridised
arrays were scanned on a ScanArray Express HT instrument
(Perkin Elmer Life and Analytical Sciences BV, Groningen, The
Netherlands). Fluorescence intensities were determined using
ImaGene software version 6.0 (Biodiscovery, El Segundo, CA,
USA), uploaded into the CMF database (CMFdb, http://
cmfdb.nki.nl) and normalised using the lowess subarray method.
Both raw and normalised data have been deposited in NCBI’s Gene
Expression Omnibus (Edgar et al, 2002) and are accessible through
GEO Series accession number GSE14513 (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc¼GSE14513).
Analyses on normalised data were performed using BRB-
ArrayTools developed by Dr Richard Simon and the BRB-ArrayTools
Development Team (http://linus.nci.nih.gov/BRB-ArrayTools.html).
Supervised class comparisons (Supplementary information and
Supplementary Table S1) were performed to select genes with
differential expression in cell lines grouped according to the
presence of the retrovirus in a particular cVIS (Van Agthoven et al,
2009b). Hierarchical clustering was carried out with Spotfire
DecisionSite 9.0 (Tibco, Somerville, MA, USA). To analyse selected
genes in human breast cancer microarray data (Wang et al, 2005),
spots were linked to Affymetrix probe sets using Entrez Gene and
Ensemble identifiers (Supplementary Table S2).
Patient samples
The protocol to study biological markers associated with disease
outcome was approved by the medical ethics committee of the
Erasmus Medical Center Rotterdam, The Netherlands (MEC
02.953). This retrospective study used 791 blindly coded, ERa
protein-positive (X10fmol/mg of protein) primary tumour
tissues, in accordance with the Code of Conduct of the Federation
of Medical Scientific Societies in the Netherlands (http://
www.fmvv.nl). This report is as much as possible in line with the
REMARK guidelines (McShane et al, 2006). Primary breast
tumours were obtained from patients with detailed clinical
follow-up as previously described (Sieuwerts et al, 2006, 2007;
Jansen et al, 2007; Meijer et al, 2008, 2009; Van Agthoven et al,
2009a). All patients underwent breast surgery for breast cancer
from 1978 through 2000. ERa status was determined by routine
ligand-binding assays or by enzyme immunoassays (Foekens et al,
1989). Further patient characteristics are summarised in Supple-
mentary Table S3.
To evaluate the impact of individual genes on tamoxifen
resistance, 296 patients who received tamoxifen monotherapy as
first-line treatment for advanced disease were included (Sieuwerts
et al, 2005). Of these patients, 10% presented with distant
metastasis at diagnosis (Supplementary Table S3). None of these
patients (43% node negative) had received prior adjuvant
hormonal therapy, whereas 56 patients had received prior adjuvant
chemotherapy (22 patients anthracycline based (FAC/FEC), 34
patients non-anthracycline based (CMF)). All patients were
routinely followed up as previously described (Martens et al,
2005; Meijer et al, 2008). The type of response to tamoxifen
therapy was assessed according to standard criteria (Hayward
et al, 1977; EORTC Breast Cancer Cooperative Group, 2000).
Clinical benefit, defined as objective tumour response or no
change lasting longer than 6 months, was observed in 185 patients
(62.5%); 13 achieved complete remission, 38 partial remission and
the remaining 134 patients experienced no change lasting longer
than 6 months. A total of 111 patients did not experience clinical
benefit (94 progressive disease and 17 no change less than or equal
to 6 months). The median time to progression was 8.5 months. The
median follow-up time after start of therapy of patients alive
(n¼78) was 38.7 months.
For the analysis of the association of individual genes with
tumour aggressiveness, 620 lymph node-negative (LNN) patients
with ERa protein-positive tumours were included (Supplementary
Table S3). Of these patients, 52% had undergone breast-conserving
lumpectomy and 100% node dissection. Adjuvant radiotherapy
was administered to 58% of the patients, none of whom had
received adjuvant systemic therapy. Distant recurrences were
observed in 215 patients (34.7%), and the median follow-up for
patients alive (n¼427) was 93.4 months. A total of 193 deaths were
recorded.
Quantitative reverse transcription (RT)–PCR of breast
tumours
RNA isolation, cDNA synthesis, quality control checks and
normalisation of data on a set of three reference genes (HPRT1,
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(Sieuwerts et al, 2005; Meijer et al, 2008). Real-time quantitative
RT–PCR was performed using the Stratagene Mx3000P QPCR
System (Agilent Technologies, Waldbronn, Germany), Assay-on-
Demand kits for CITED2 (Hs00366696_m1) and NCOR2
(Hs00196955_m1) from Applied Biosystems (Nieuwerkerk a/d
IJssel, The Netherlands), and the ABsolute qPCR Low ROX master
Mix from Abgene Ltd (Epsom, UK). Quantification of ESR1, PGR
and MKI67 mRNA levels was performed as described (Sieuwerts
et al, 2005, 2007).
Statistical analyses
For statistical computations, STATA statistical package 10.0
(STATA Corp., College Station, TX, USA) was used. Differences
in levels between groups were assessed using the Mann–Whitney
U-test or the Kruskal–Wallis test, including a Wilcoxon-type test
for trend, when appropriate. In these tests, patient and tumour
characteristics were used as grouping variables. The strength of the
association between continuous variables was tested with Spear-
man’s rank correlation (rs). To reduce skewness, most variables
were log- or Box-Cox transformed. The Cox proportional hazards
model was used to calculate the hazard ratio (HR) and its 95%
confidence interval (CI) in the analyses of metastasis-free survival
(MFS), overall survival (OS) and progression-free survival (PFS).
MFS was defined as the time between surgical removal of the
primary tumour and the first detection of a distant metastasis, as
revealed after symptoms were reported by the patient, the
occurrence of clinical signs or at regular follow-up. Death from
any cause was considered an event for OS. For advanced patients
treated with tamoxifen, PFS was defined as the time elapsed
between initiation of tamoxifen therapy and the first detection of
progression of the disease. The proportional hazards assumption
was not violated for MFS, as verified by a test based on Schoenfeld
residuals. The proportional hazards assumption was violated for
PFS, but not when follow-up was censored at 9 months as
described previously (Sieuwerts et al, 2005). Logistic regression
analysis was used to examine the relation of mRNA levels with
clinical benefit of tamoxifen therapy, and for the calculation of the
Odds Ratio (OR) and its 95% CI. A two-sided P-value of o0.05 was
considered to be statistically significant.
RESULTS
Gene expression profiles of tamoxifen-resistant cell lines
are very similar
As all tamoxifen-resistant cell lines generated by insertion
mutagenesis were derived from a single parental cell line (Dorssers
et al, 1993; Van Agthoven et al, 2009b), it was hypothesised that
differences in gene expression profiles would reflect the underlying
mechanisms by which the retrovirally targeted genes induced
tamoxifen resistance. From a total of 69 out of 79 cell lines, high-
quality total RNA from two independent cell cultures was con-
verted into double-stranded cDNA and amplified into aRNA with
T7-RNA polymerase. Fluorophore-labelled probes of tamoxifen-
resistant cell lines were hybridised onto a 35K oligonucleotide
array containing approximately 28000 annotated human genes,
and compared with a reference probe derived from a panel of
stable cell lines (Jansen et al, 2005). Our tamoxifen-resistant cell
line panel showed clearly different gene expression patterns when
compared with oestrogen-stimulated or tamoxifen-arrested
parental ZR-75-1 cells (not shown).
Among the tamoxifen-resistant cell lines, unsupervised
hierarchical clustering revealed very similar expression profiles
(Supplementary Figure S1, 15376 genes) and did not group the
bulk of cell lines belonging to a particular cVIS (Van Agthoven
et al, 2009b). Only cell lines with a viral integration in NCOR2 were
mostly positioned in close proximity within the dendrogram
(Supplementary Figure S1, not indicated).
Subsequently, a class comparison analysis in which cell lines
were organised according to the presence of a retrovirus in the
same chromosomal region (Van Agthoven et al, 2009b) was
performed. Between cell lines with an integration near BCAR1 or
BCAR3, very few differences were observed, in accordance with the
results of our previous analysis of BCAR1-o rBCAR3-transfected
cells (Dorssers et al, 2005). Therefore, these cell lines were
combined and used as the reference group for class comparison
with each of the other groups of cell lines. All genes showing
significant differences (Po0.001; N¼1106, Supplementary Table
S1) were pooled. After excluding genes showing a dye bias, 251
spots (representing 194 unique annotated genes) were left for
hierarchical clustering analysis. The cell lines were organised into
groups having a retroviral integration in the same chromosomal
region (Figure 1 and Supplementary Figure S2). Cell lines
belonging to the NCOR2 group showed the most prominent
differences, having a higher expression of many genes, compared
with the other tamoxifen-resistant cell lines. The retroviral target
gene in the integration locus (NCOR2) was robustly upregulated in
these cell lines (Figure 1, most right arrow). In agreement with the
increased expression, western blot analysis confirmed that NCOR2
protein levels were increased in these cell lines (Supplementary
Figure S3). The cell lines with an integration in the CITED2 locus
also showed an altered expression of several genes, including
strongly increased levels of the targeted CITED2 gene (Figure 1).
This is in agreement with the previously established overexpres-
sion of CITED2 mRNA and protein in these cell lines (Van
Agthoven et al, 2009b). Individual cell lines with a retroviral
integration near AKT2 or TRERF1 showed different expression
patterns, suggesting clonal variation (Figure 1). Cell lines with
integrations within cVIS5, 7, 10 or 11 (for which the responsible
target genes have not yet been established (Van Agthoven et al,
2009b)) and cell lines lacking a common virus integration site did
not show strongly different expression patterns (Supplementary
Figure S2). Our class comparison analyses revealed a novel target
gene (TSHZ1) in the cVIS6 locus, which was sevenfold upregulated
as a consequence of virus integration (Supplementary Figure S2,
arrow), but in this cell line, global gene expression was only
minimally changed.
From these results, we conclude that in many cell lines, the gene
causative for oestrogen independency did not impose a distinct
and permanent expression phenotype. Only the virus integrations
near NCOR2 and CITED2 caused a shift in gene expression.
NCOR2 gene signature correlates with molecular subtypes
in ER-positive breast cancer patients
To analyse the clinical relevance of 171 genes differentially
expressed in cell lines with a retroviral integration in NCOR2,
compared with cell lines with an integration in BCAR1 and BCAR3
(Supplementary Table S2), we performed hierarchical clustering of
the expression data from our series of 221 ER-positive breast
tumours of LNN patients who did not receive adjuvant systemic
therapy (Wang et al, 2005). Surprisingly, hierarchical clustering
(Supplementary Figure S4a, Supplementary Information) of these
genes resulted in a sample dendrogram, which showed a strong
correlation with the molecular subtypes of these tumours (Perou
et al, 2000; Smid et al, 2008). A detailed inspection showed that one
branch consisted of tumours belonging to the normal-like and
ERBB2 subtypes and nearly half of the tumours of luminal A-type
(group A), whereas the two other groups contained tumours
predominantly belonging to the luminal A- or B subtype (groups B
and C). Patients with tumours belonging to cluster group A
showed a prolonged MFS when compared with the MFS of the
other two groups of patients (Supplementary Figure S4b).
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sRole of CITED2 and NCOR2 in breast cancer aggressiveness
and tamoxifen resistance
Given the impact of the viral integrations within NCOR2 and
CITED2 on the overall mRNA expression in our cell model, we
established their relationships with clinical parameters reflecting
tamoxifen resistance and tumour aggressiveness. The mRNA levels
of these two genes were determined in primary ERa-positive
tumours by quantitative RT–PCR and normalised to three
reference genes. A correlation was observed between NCOR2 and
CITED2, NCOR2 and MKI67, and between CITED2 and ESR1
(rs40.20, Po0.0001) (Supplementary Table S4). Increasing
CITED2 mRNA levels were correlated with older age and post-
menopausal status. Lower NCOR2 levels correlated with a higher
grade (Supplementary Table S4).
For the analysis of association with tamoxifen treatment, 296
patients who received tamoxifen as first-line treatment for
advanced disease (Supplementary Table S3) were included. In
the univariate logistic regression analysis, high CITED2 mRNA
levels were significantly associated with clinical benefit, both as a
continuous (OR¼1.34, P¼0.028, Table 1) and as a categorised
variable (median, OR¼2.20, P¼0.001). In multivariate analyses
including the traditional predictive factors (that is, age and
menopausal status at the start of tamoxifen therapy, disease-free
interval, dominant site of relapse and ESR1 and PGR mRNA
levels), high CITED2 levels remained significantly associated with
clinical benefit (Table 1). Continuous CITED2 mRNA levels were of
borderline significance for PFS. When divided into two equally
sized groups, high levels of CITED2 mRNA were associated with
favourable PFS, independently of traditional predictive factors
(Table 1). In contrast, NCOR2 mRNA levels as a continuous or as a
categorised variable were not significantly associated with clinical
benefit or PFS (Table 1). The results of the multivariate analyses
with adjuvant chemotherapy as an additional variable showed that
the estimates of the coefficients of individual genes were similar.
For the analysis of tumour aggressiveness, 620 ERa-positive
tumours of LNN patients who did not receive any systemic
adjuvant treatment were included (Supplementary Table S3). In
the analysis of MFS and OS, high levels of NCOR2 mRNA (both as a
continuous and categorised variable, Table 2) were associated with
a favourable outcome. The Kaplan–Meier analysis visualises the
different outcomes of patients stratified according to the median
level of NCOR2 (Figure 2A). In a multivariate analysis including
traditional prognostic factors (age, menopausal status, tumour
size, grade and ESR1 and PGR mRNA levels), NCOR2 mRNA levels
were significantly associated with a favourable MFS (median,
HR¼0.68, P¼0.006) and OS (Table 2). The analysis of CITED2
showed similar results. High levels of CITED2, both as a
continuous and categorised variable, were significantly associated
with prolonged MFS (Table 2). Kaplan–Meier curves illustrate the
different outcomes for patients stratified according to the median
CITED2 mRNA level (Figure 2B). These associations with MFS
were independent of the classical prognostic factors (HR¼0.71,
P¼0.017, Table 2).
DISCUSSION
Insertion mutagenesis with retroviruses is a powerful tool to
identify genes involved in sensitivity to anti-cancer agents. With
AKT2
n=2
BCAR1
n=6
BCAR3
n=9
CITED2
n=2 n=2
EGFR NCOR2
n=5
TRERF1
n=3
Figure 1 Hierarchical clustering of 251 genes in tamoxifen-resistant breast cancer cell lines. Cell lines (three hybridisations each) were grouped together
according to the location of the retrovirus in the cellular genome (columns). The number of different cell lines in a group is indicated below the name. Genes
(rows) were selected by class comparison analysis and clustering was performed using the unweighted pair-group method with arithmetic mean in Spotfire.
Gene expression above the mean is shown in white, that below the mean is indicated in black. Target genes in the integration loci are marked with arrows
(from left to right: BCAR1, BCAR3, CITED2 and NCOR2). The order of the genes, their names and identifiers are provided in Supplementary Table S1.
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sthis approach, we have been able to identify several genes
conferring tamoxifen resistance in vitro (Van Agthoven et al,
1998, 2009b; Brinkman et al, 2000). To obtain a better insight into
the mechanisms by which these genes induce tamoxifen resistance,
we assessed whether differences in gene expression patterns
existed between the different groups of tamoxifen-resistant cell
lines. We found that most groups of cell lines showed a very
similar pattern of gene expression, but that cell lines with a
retroviral integration near NCOR2 or CITED2 showed a different
gene expression profile. NCOR2 and CITED2 both function as
regulators of transcription and therefore altered gene expression
patterns could be expected by their deregulation. In contrast, other
nuclear regulators (such as TRERF1), did not significantly change
the expression profile. Importantly, for some groups of cell lines
(for example, those with insertions near the AKT2 gene),
differences in gene expression patterns were observed among the
independently derived cell lines, suggesting clonal variations not
related to the specific target gene. These observations imply that
the changes in gene expression in unique cell lines not belonging
to a cVIS cannot be interpreted as the consequence of the specific
retroviral integration event. Our results strongly suggest that,
although the targeted genes had a crucial role in the establishment
of the resistant phenotype (Van Agthoven et al, 1998, 2009b;
Brinkman et al, 2000), ultimately these isogenic cell lines
developed a common gene expression programme compatible
with growth in the presence of tamoxifen. Additional hybridisation
experiments involving transfectants with an inducible expression
are required to further resolve the gene expression differences
caused by the action of these genes and the underlying resistance
pathways (Creighton et al, 2008). An alternative explanation may
be that the deregulation of most targeted genes only caused post-
transcriptional modifications, such as differences in the activation
state of important signalling proteins, without affecting their
mRNA levels. Such events cannot be measured by gene expression
profiling but need to be assessed using other techniques (Korf
et al, 2008; Schuchardt and Borlak, 2008; Speer et al, 2008).
The analysis of the expression data of the gene set associated with
a retroviral integration within NCOR2 in our cell model identified
patients with ERa-positive breast cancer with different MFS
(Supplementary Figure S4). The best-performing group of patients
revealed by this gene signature had tumours predominantly of the
luminal A, normal-like or ERBB2 molecular subtypes. These
findings suggest that the genes associated with NCOR2 activation
in our cell model correlate with the well-established molecular
breast cancer subtypes (Perou et al, 2000) and thereby may provide
prognostic information for ERa-positive breast cancer.
Table 1 Progression-free survival (PFS) and clinical benefit after first-line tamoxifen treatment of 296 patients with ER+ primary breast tumours
PFS
a Clinical benefit
Univariate Multivariate Univariate Multivariate
N HR 95% CI P-value HR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
Age at start of therapy (years) 0.048 NS NS NS
p40 17 1 1 1 1
41–55 100 0.69 0.37–1.30 0.62 0.32–1.19 0.89 0.31–2.53 0.81 0.26–2.52
56–70 105 0.59 0.31–1.11 0.54 0.24–1.25 1.34 0.47–3.82 0.88 0.23–3.40
470 74 0.41 0.21–0.82 0.38 0.16–0.92 1.46 0.49–4.30 0.99 0.25–3.98
Menopausal status at start of therapy NS NS 0.096 NS
Pre 77 1 1 1 1
Post 219 0.74 0.52–1.06 1.07 0.63–1.81 1.57 0.92–2.66 1.27 0.55–2.94
Disease-free interval (years) o0.001 o0.001 o0.001 o0.001
p17 4 1 1 1 1
1–3 134 0.46 0.32–0.67 0.48 0.33–0.71 3.52 1.94–6.38 3.49 1.88–6.46
43 88 0.39 0.25–0.61 0.40 0.26–0.64 3.91 2.03–7.55 3.89 1.95–7.77
Dominant site of relapse NS NS NS NS
LR 3 3 1 1 1 1
Bone 154 1.24 0.70–2.19 1.21 0.66–2.20 0.63 0.28–1.41 0.57 0.24–1.38
Viscera 109 1.17 0.65–2.11 1.28 0.69–2.37 0.81 0.35–1.88 0.65 0.26–1.62
ESR1 mRNA level
Continuous 0.87 0.80–0.94 o0.001 0.88 0.81–0.96 0.005 1.21 1.08–1.36 0.001 1.20 1.05–1.37 0.007
PGR mRNA level
Continuous 0.93 0.86–1.01 0.087 0.95 0.87–1.03 0.021 1.11 0.99–1.25 0.079 1.06 0.93–1.21 NS
Factors analysed Additions to the base model
b Additions to the base model
b
NCOR2
Continuous 1.06 0.84–1.34 NS 1.12 0.89–1.41 NS 0.88 0.63–1.23 NS 0.79 0.55–1.13 NS
Median 1.13 0.81–1.57 NS 1.19 0.85–1.65 NS 0.87 0.54–1.39 NS 0.77 0.46–1.28 NS
CITED2
Continuous 0.84 0.70–1.00 0.058 0.94 0.77–1.14 NS 1.34 1.03–1.76 0.028 1.17 0.86–1.59 NS
Median 0.58 0.42–0.81 0.001 0.65 0.46–0.93 0.017 2.20 1.36–3.57 0.001 1.91 1.12–3.25 0.017
Abbreviations: CI¼confidence interval; HR¼hazard ratio; NS¼P-values 40.10; L R¼local regional; OR¼odds ratio.
aPFS was censored at 9 months, to avoid violation of the
proportional hazards assumption.
bFactors were separately introduced to the base multivariate model that included the factors age, menopausal status, disease-free interval,
dominant site of relapse, ESR1 and PGR mRNA levels.
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sAs viral integrations in both NCOR2 and CITED2 yielded
differences in gene expression patterns in our cell model, we
quantified their mRNA levels in breast cancer tissues to further
investigate the role of these two genes in tumour aggressiveness
and resistance to tamoxifen. Our results showed that in LNN
patients with ERa-positive primary tumours who had not received
systemic adjuvant treatment, high mRNA levels of NCOR2 and
CITED2 were associated with a longer MFS independently of the
traditional prognostic factors. Preliminary analyses in a subset of
120 patients for whom the molecular breast cancer subtype was
known suggest that NCOR2 and CITED2 mRNA levels are
particularly prognostic in patients with luminal A tumours, but
not luminal B tumours (data not shown). In addition to its
association with tumour aggressiveness, high levels of CITED2
mRNA were also significantly associated with clinical benefit of
tamoxifen treatment in advanced breast cancer independently of
the traditional predictive markers including adjuvant chemo-
therapy. This finding further emphasises the role of CITED2 in
tamoxifen resistance.
NCOR2 participates in a co-repressor complex resulting in
chromatin condensation and may also modulate ligand dependency
of hormone receptors and contribute to oestrogen independency
(Shou et al, 2004; Perissi and Rosenfeld, 2005). Furthermore,
NCOR2 was shown to be a key regulator of neuronal stem cell
differentiation by the repression of a specific histone demethylase
(Jepsen et al, 2007). In a recent study by Green et al (2008),
immunohistochemical analyses of tissue microarrays have indicated
that moderate/high levels of NCOR2 protein, as found in 16.7% of
tumours, are associated with poor prognosis of breast cancer
patients. The differences in patient outcome, compared with the
findings in our study, may be explained by the different targets
measured (mRNA vs protein) and/or the different composition of
patient groups. The study population explored by Green et al (2008)
consisted of both ERa-negative and -positive tumours, patients with
lymph node-positive and -negative disease, whereas patients
received adjuvant systemic treatment according to their Nottingham
Prognostic Index. In contrast, our study population is a homo-
geneous set of ERa-positive tumours of LNN patients who did not
receive adjuvant systemic therapy, which allowed the assessment of
the natural course of the disease. The importance of the selection of
study groups is illustrated by the fact that we did not observe a
relationship between NCOR2 mRNA levels and MFS in patients
with ERa-negative tumours (data not shown), contrasting with our
findings in ERa-positive tumours (Table 2). It is noteworthy that the
association of high NCOR2 levels with a favourable outcome in
breast cancer patients seems to be in conflict with our cell line data,
which showed increased NCOR2 mRNA and protein levels in
tamoxifen-resistant cell lines (Figure 1 and Supplementary Figure
S3). As we were unable to confirm the dominant role of NCOR2 in
our cell model (Van Agthoven et al, 2009b) and did not establish an
association with tamoxifen resistance, it is premature to speculate
about mechanistic differences.
For CITED2, no information regarding the outcome of breast
cancer patients was available. Its family member, CITED4, has
Table 2 Metastasis-free survival (MFS) and overall survival (OS) of 620 lymph node-negative patients with ER+ primary breast tumours
MFS OS
Univariate Multivariate Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Age (years) 0.005 0.066 NS NS
p40 1 1 1 1
41–55 0.76 0.50–1.14 0.81 0.53–1.24 0.88 0.55–1.41 0.92 0.57–1.50
56–70 0.54 0.35–0.83 0.45 0.24–0.87 0.80 0.49–1.30 0.61 0.3–1.26
470 0.48 0.29–0.78 0.39 0.19–0.78 1.20 0.73–1.97 0.95 0.45–2.00
Menopausal status 0.013 NS NS NS
Pre 1 1 1 1
Post 0.71 0.54–0.93 1.08 0.64–1.81 1.12 0.84–1.50 1.24 0.7–2.20
Tumour size 0.074 NS NS NS
p2cm 1 1 1 1
42cm 1.28 0.98–1.67 1.26 0.95–1.66 1.24 0.93–1.64 1.14 0.85–1.53
Grade 0.002 0.002 0.069 NS
Poor 1 1 1 1
Unknown 1.03 0.77–1.38 1.13 0.83–1.52 1.01 0.74–1.39 1.03 0.74–1.42
Moderate/good 0.53 0.35–0.79 0.55 0.36–0.83 0.65 0.44–0.98 0.70 0.47–1.06
ESR1 mRNA level
Continuous 0.96 0.91–1.02 NS 1.06 0.99–1.13 NS 0.99 0.93–1.05 NS 1.03 0.96–1.11 NS
PGR mRNA level
Continuous 0.91 0.85–0.97 0.003 0.90 0.84–0.96 0.002 0.89 0.83–0.95 0.001 0.88 0.81–0.94 o0.001
Factors analysed Additions to the base model
a Additions to the base model
a
NCOR2
Continuous 0.63 0.50–0.78 o0.001 0.67 0.54–0.83 o0.001 0.75 0.60–0.95 0.016 0.78 0.62–0.98 0.032
Median 0.62 0.47–0.82 0.001 0.68 0.51–0.89 0.006 0.73 0.55–0.97 0.031 0.78–0.58 1.04
CITED2
Continuous 0.69 0.58–0.84 o0.001 0.77 0.63–0.93 0.008 0.90 0.74–1.09 NS 0.90 0.73–1.11 NS
Median 0.62 0.47–0.82 0.001 0.71 0.53–0.94 0.017 0.73 0.55–0.97 0.028 0.75 0.55–1.01 0.054
Abbreviations: CI¼confidence interval; HR¼hazard ratio; NS¼P-value 40.10.
aFactors were separately introduced to the base multivariate model that included the factors
age, menopausal status, tumour size, grade, ESR1 and PGR mRNA levels.
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sbeen analysed in breast tumours and was found to be associated
with HIF1a expression and to be either lost or translocated into the
cytoplasm during tumour progression (Fox et al, 2004). CITED2
acts as a transcriptional co-factor and may regulate HIF1-
stimulated apoptosis through FOXO3a (Bakker et al, 2007).
CITED2 expression is regulated by protein arginine methyltrans-
ferases, which modulate histone and chromatin proteins
(Kleinschmidt et al, 2008). Loss of CITED2 has been implicated
in restored sensitivity to platinum compounds in resistant ovarian
cancer cells (Yanagie et al, 2009) and in increased invasiveness in a
colon cancer model (Bai and Merchant, 2007). In line with these
observations, reduced CITED2 mRNA levels are a marker of poor
prognosis in breast cancer patients. In contrast, in our cell line
model, it was suggested that overexpression caused tamoxifen
resistance (Figure 1). Our transfection experiments have not yet
been successful in confirming this speculation (Van Agthoven
et al, 2009b).
In summary, our functional genetic screen by retroviral
insertion mutagenesis has identified several genes that are causal
or strongly implicated in anti-oestrogen resistance of breast cancer
cells. Although all tamoxifen-resistant cell lines obtained through
this approach showed a gene expression profile distinct from
parental cells, among these tamoxifen-resistant cell lines, expres-
sion patterns were nearly indistinguishable from each other. In
these cases, alteration of signalling cascades leading to tamoxifen
resistance may occur at the post-transcriptional level, such as
protein activation status, which is not translated into different gene
expression patterns. In contrast, cell lines with viral integrations
affecting NCOR2 and CITED2 expression, showed different gene
expression patterns when compared with the other tamoxifen-
resistant cell lines. Importantly, our experiments have shown that
NCOR2, CITED2 and other genes previously revealed through
functional screening (Van Agthoven et al, 2009a) are implicated in
breast cancer outcome and therefore bear clinical relevance. On
the basis of these results, further studies into the mechanisms of
tamoxifen resistance of these cell line models are warranted to
identify novel targets for therapy, as well as novel prognostic and
predictive markers. Ultimately, this could result in improved
outcome to endocrine therapy and to a more individualised
management of breast cancer patients.
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